scholarly journals Full-thickness macular hole formation following antivascular endothelial growth factor injection in a case of hemicentral retinal vein occlusion

2021 ◽  
Vol 14 (1) ◽  
pp. 49
Author(s):  
Srijita Mitra ◽  
Sahil Sarpal ◽  
Abhijit Chattopadhyay ◽  
Subhankarsri Paul ◽  
JonakiGhosh Roy
2011 ◽  
Vol 2011 ◽  
pp. 1-3 ◽  
Author(s):  
Manish Nagpal ◽  
Vikram Mehta ◽  
Kamal Nagpal

Macular edema secondary to retinal vein occlusion is commonly being treated with off-label intravitreal bevacizumab with good outcomes. A significant reduction in macular edema and improvement in visual acuity is seen following such a treatment with no serious adverse effects. In the reported case, a full-thickness macular hole was noticed one month after intravitreal bevacizumab for macular edema secondary to hemicentral retinal vein occlusion. On a detailed review of the pre- and postoptical coherence tomography scans, it was realized that there was a preexisting stage 2-3 macular hole which was masked by the hemorrhages and edema at the fovea and the macular hole had progressed following the injection.


2021 ◽  
pp. bjophthalmol-2021-319180
Author(s):  
Mirataollah Salabati ◽  
Raziyeh Mahmoudzadeh ◽  
Jae-Chiang Wong ◽  
Dillan Patel ◽  
Samir N Patel ◽  
...  

Background/aimsTo evaluate the outcomes of eyes with macular oedema due to retinal vein occlusion (RVO) that are lost to follow-up (LTFU) after antivascular endothelial growth factor (VEGF) injections.MethodA retrospective, single-centre, consecutive case series of RVO patients receiving injections who were LTFU >6 months was conducted. Data were collected from the visit before LTFU; return visit; 3 months, 6 months and 12 months after return; and the final visit.ResultsNinety eyes of 83 patients were included. Fifty (55.5%) eyes had branch RVO and 40 (44.5%) had central RVO. Mean LTFU duration was 277.8 days with additional mean follow-up for 748.1 days after return. Mean logarithm of the minimum angle of resolution visual acuity (VA) (Snellen) at the visit before LTFU was 0.72 (20/105) which worsened on return [1.04 (20/219), p<0.001) and remained worse at all timepoints after return: 0.92 (20/166) at 3 months (p<0.001), 0.97 (20/187) at 6 months (p<0.001), 0.94 (20/174) at 12 months (p<0.001) and 1.01 (20/205) at final visit (p<0.001). Mean central foveal thickness (CFT) increased from 252 µm at the visit before LTFU to 396 µm at the return visit (p<0.001). No difference in CFT was noted by 3 months (258 µm, p=0.71), 6 months (241 µm, p=0.54) or 12 months after return (250 µm, p=0.95). CFT was thinner at the final visit (215 µm, p=0.018).ConclusionRVO patients receiving anti-VEGF injections who were LTFU experienced a decline in VA that did not return to the levels seen before LTFU despite improvement in CFT after restarting therapy, underscoring the importance of ongoing treatment.


Retina ◽  
2007 ◽  
Vol 27 (4) ◽  
pp. 473-476 ◽  
Author(s):  
HIDEKI KOIZUMI ◽  
JASON S. SLAKTER ◽  
RICHARD F. SPAIDE

2017 ◽  
Vol Volume 12 ◽  
pp. 911-915 ◽  
Author(s):  
Stamatina Kabanarou ◽  
Tina Xirou ◽  
George Mangouritsas ◽  
Christina Garnavou-Xirou ◽  
Eirini Boutouri ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document